A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia.
about
Role of Complement in Autoimmune Hemolytic AnemiaTreatment Options for Primary Autoimmune Hemolytic Anemia: A Short Comprehensive ReviewTreatment of autoimmune hemolytic anemiasRed blood cell destruction in autoimmune hemolytic anemia: role of complement and potential new targets for therapyRituximab in the treatment of autoimmune haemolytic anaemiaRituximab therapy in pemphigus and other autoantibody-mediated diseases.Warm autoimmune hemolytic anemia: experience from a single referral center in Mexico City.The preclinical discovery of rituximab for the treatment of non-Hodgkin's lymphoma.Current treatment strategies in autoimmune hemolytic disorders.Benefits of rituximab as a second-line treatment for autoimmune haemolytic anaemia in children: a prospective French cohort study.A randomized and double-blind controlled trial evaluating the safety and efficacy of rituximab for warm auto-immune hemolytic anemia in adults (the RAIHA study).Probability of remaining in unsustained complete remission after steroid therapy withdrawal in patients with primary warm-antibody reactive autoimmune hemolytic anemia.A monocentric retrospective study comparing pulse cyclophosphamide therapy versus low dose rituximab in the treatment of refractory autoimmune hemolytic anemia in adults.The diagnosis and management of primary autoimmune haemolytic anaemia.Acute autoimmune hemolytic anemia due to anti-Ena autoantibody successfully treated with rituximab.The use of rituximab to prevent severe delayed haemolytic transfusion reaction in immunized patients with sickle cell disease.Characteristics and outcome of warm autoimmune hemolytic anemia in adults: New insights based on a single-center experience with 60 patients.Rituximab is an effective and safe treatment of relapse in elderly patients with resistant warm AIHA.Autoimmune haemolytic anaemia
P2860
Q26773175-49C31E28-F161-4FF3-9D9B-039AF75D2751Q26773178-82F0619C-8333-46E1-B4B8-0A74415FA362Q26866954-8AE66086-86C8-4CD2-AC4D-3123666C62D7Q27013581-781498EB-E27F-497C-9B6C-47B500C399C4Q27023114-6BAE73FF-F720-4739-A4A2-85DEDE391D3DQ37620483-187EF2D0-7510-4A12-8680-3732B00B3B11Q37740414-F1D9D602-FBEF-478E-858F-89E442775D90Q38530254-5710291F-F52C-42F1-AF67-114DF64432F5Q38581833-88BDCB71-D3E8-4933-92FD-0FF6378ABF90Q38819009-2E48355F-D906-4636-9316-0BA488628963Q39328482-B8FE441F-2915-4E37-B769-12C062278A91Q40503894-F982FC9A-3F59-451F-8550-0A76116F9B37Q40626008-7AF5F737-8D0A-435A-A26D-7F9495118426Q48124799-D360FA2B-F3E8-4EBA-B1BB-559EA5C78D9EQ50098670-30885263-AF1E-4AA7-A1B7-14C12670BE2DQ50454968-0D8E74CD-CC88-4748-851B-3DE5044EA191Q51733656-301B3B9F-0665-4AB7-9414-A00A4CE4712BQ53798218-1DDDE53C-9467-435D-B60C-DAECA613E771Q57655172-594481C4-852A-4E96-A227-3C10CCE2DAEB
P2860
A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
A phase III randomized trial c ...... autoimmune haemolytic anaemia.
@en
A phase III randomized trial c ...... autoimmune haemolytic anaemia.
@nl
type
label
A phase III randomized trial c ...... autoimmune haemolytic anaemia.
@en
A phase III randomized trial c ...... autoimmune haemolytic anaemia.
@nl
prefLabel
A phase III randomized trial c ...... autoimmune haemolytic anaemia.
@en
A phase III randomized trial c ...... autoimmune haemolytic anaemia.
@nl
P2093
P2860
P356
P1476
A phase III randomized trial c ...... autoimmune haemolytic anaemia
@en
P2093
Claudia Schöllkopf
Dorthe Rønnov-Jessen
Hanne Vestergaard
Henrik Birgens
Herdis Larsen
Inge H Rasmussen
Lars Kjeldsen
Ove J Nielsen
Tobias W Klausen
Torben Mourits-Andersen
P2860
P304
P356
10.1111/BJH.12541
P407
P577
2013-08-24T00:00:00Z